Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
Farias DLC, Prats J, Cavalcanti AB, Rosa RG, Machado FR, Berwanger O, Azevedo LCP, Lopes RD, Avezum Á, Kawano-Dourado L, Damiani LP, Rojas SSO, Oliveira CZ, Andrade LEC, Sandes AF, Pintão MC, Castro Júnior CG, Scheinberg P, Veiga VC.
Farias DLC, et al. Among authors: azevedo lcp.
Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):337-347. doi: 10.5935/0103-507X.20200060.
Rev Bras Ter Intensiva. 2020.
PMID: 32965395
Free PMC article.